World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
76166
World Ranking
5865
National Ranking
169

Overview

Stéphane Oudard is affiliated with Hôpital Européen Georges-Pompidou in France. Their research primarily focuses on medicine, with particular emphasis on pulmonary and respiratory medicine, oncology, surgery, cancer research, and molecular biology.

The scientist has significant contributions in key topics including:

  • Renal cell carcinoma treatment
  • Cancer immunotherapy and biomarkers
  • Prostate cancer treatment and research
  • Bladder and urothelial cancer treatments
  • Cancer genomics and diagnostics
  • Renal and related cancers
  • Radiopharmaceutical chemistry and applications

Stéphane Oudard's recent papers include:

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (2021) published in New England Journal of Medicine
  • Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer (2022) published in Immunity
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial (2021) published in The Lancet Oncology
  • ctDNA guiding adjuvant immunotherapy in urothelial carcinoma (2021) published in Nature
  • Bone health in cancer: ESMO Clinical Practice Guidelines (2020) published in Annals of Oncology

The frequent co-authors with whom Stéphane Oudard has collaborated include Brigitte Laguerre, Gwénaëlle Gravis, Yann Vano, Philippe Barthélémy, and Laurence Albigès.

The venues where the scientist has published most frequently are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Lancet Oncology
  • European Journal of Cancer
  • European Urology

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Matthew R Smith;Fred Saad;Simon Chowdhury;Stéphane Oudard

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Gwenaelle Gravis;Karim Fizazi;Florence Joly;Stéphane Oudard

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

    Cécile Badoual;Stéphane Hans;Nathalie Merillon;Cordélia Van Ryswick

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Toni K. Choueiri;Piotr Tomczak;Se Hoon Park;Balaji Venugopal

  • Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

    Toni K. Choueiri;Anne Plantade;Paul Elson;Sylvie Negrier

  • Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

    Gwenaelle Gravis;Jean-Marie Boher;Florence Joly;Michel Soulié

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

    Thomas J. Mitchell;Samra Turajlic;Andrew Rowan;David Nicol

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Alain Ravaud
Alain Ravaud University of Bordeaux
Fred Saad
Fred Saad University of Montreal
Christine Chevreau
Christine Chevreau DuPont (United States)
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career, there are several online degree options and specialized pathways to explore beyond a traditional MD program. For those interested in advanced nursing roles, pursuing a cheapest dnp programs can be a cost-effective way to earn a Doctor of Nursing Practice and advance into leadership or clinical expert roles.

Pharmacists are in high demand, and accredited pharmd online programs offer flexibility for working professionals or those balancing other commitments while earning their Doctor of Pharmacy degree.

Interested in healthcare administration or data management? You can start a promising career by enrolling in online rhit degree programs, which prepare you for the Registered Health Information Technician (RHIT) certification and open doors to roles centered on health data systems.

For those seeking a quicker path into healthcare, understanding the average cost of medical billing and coding program can help you start a career in medical billing and coding, a vital area with growing job prospects and remote work flexibility.

Best Scientists Citing Stéphane Oudard

Trending Scientists